EW vs. BSX, SYK, MDT, BDX, IDXX, RMD, DXCM, STE, PODD, and BAX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), and Baxter International (BAX). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences vs.
Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
Boston Scientific currently has a consensus price target of $108.91, indicating a potential upside of 4.93%. Edwards Lifesciences has a consensus price target of $79.95, indicating a potential upside of 12.04%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Boston Scientific.
Edwards Lifesciences received 281 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 70.85% of users gave Edwards Lifesciences an outperform vote while only 69.70% of users gave Boston Scientific an outperform vote.
Edwards Lifesciences has a net margin of 72.93% compared to Boston Scientific's net margin of 11.07%. Edwards Lifesciences' return on equity of 19.40% beat Boston Scientific's return on equity.
89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Boston Scientific shares are held by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Boston Scientific had 8 more articles in the media than Edwards Lifesciences. MarketBeat recorded 34 mentions for Boston Scientific and 26 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.62 beat Boston Scientific's score of 1.48 indicating that Edwards Lifesciences is being referred to more favorably in the news media.
Boston Scientific has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Edwards Lifesciences has lower revenue, but higher earnings than Boston Scientific. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Summary
Edwards Lifesciences beats Boston Scientific on 11 of the 19 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
This page (NYSE:EW) was last updated on 3/25/2025 by MarketBeat.com Staff
